| P2093 | author name string | Do-Hyun Nam | |
| | Jin Hee Kim | |
| | Jae Ho Cho | |
| | Chang-Ok Suh | |
| | Do Hoon Lim | |
| | Hyun-Cheol Kang | |
| | Il Han Kim | |
| | In Ah Kim | |
| | Kwan Ho Cho | |
| | Chul-Kee Park | |
| | Byung Ock Choi | |
| | Tosol Yu | |
| | Yong-Kil Hong | |
| | Woong-Ki Chung | |
| P2860 | cites work | ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis | Q27852494 |
| | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| | Initial treatment patterns over time for anaplastic oligodendroglial tumors | Q30419123 |
| | International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors | Q30426724 |
| | Survey of treatment recommendations for anaplastic oligodendroglioma | Q30441461 |
| | Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | Q30542081 |
| | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. | Q30778846 |
| | Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. | Q30807440 |
| | Independent association of extent of resection with survival in patients with malignant brain astrocytoma | Q33375165 |
| | A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors | Q34132883 |
| | Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. | Q34446549 |
| | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EOR | Q34523475 |
| | Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma | Q35800632 |
| | Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. | Q36898973 |
| | Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials | Q38720644 |
| | IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis | Q42096951 |
| | NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide | Q43245397 |
| | Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. | Q44754640 |
| | Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. | Q45062497 |
| | Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers | Q45275608 |
| | Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma | Q46244450 |
| | New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cance | Q46341794 |
| | Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma | Q48106629 |
| | Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. | Q48161996 |
| | Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 |
| | Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials | Q48286137 |
| | ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma | Q48446221 |
| | Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12. | Q48457980 |
| | Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial | Q48467310 |
| | What is an oligodendroglioma? | Q48629204 |
| | Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas | Q48755711 |
| | Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers | Q48910170 |
| | Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. | Q55476212 |
| P433 | issue | 1 | |
| P921 | main subject | radiation oncology | Q729267 |
| | oligodendroglioma | Q1318384 |
| | multicenter clinical trial | Q6934595 |
| | adult oligodendroglioma | Q18555324 |
| | anaplastic oligodendroglioma | Q84955701 |
| P304 | page(s) | 207-215 | |
| P577 | publication date | 2015-09-04 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12. | |
| P478 | volume | 125 | |